Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Miconazole
- Accession Number
- DB01110 (APRD01115)
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet Approved
- Description
An imidazole antifungal agent that is used topically and by intravenous infusion. [PubChem]
- Structure
Structure for DB01110 (Miconazole)
- Synonyms
- 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
- 1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
- Daktarin iv
- Miconazole
- Monistat iv (tn)
- Product Ingredients
Ingredient UNII CAS InChI Key Miconazole nitrate VW4H1CYW1K 22832-87-7 MCCACAIVAXEFAL-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Oravig Tablet 50 mg/1 Buccal Praelia Pharmaceuticals Inc 2012-11-01 2015-12-29 US 
Oravig Tablet 50 mg/1 Buccal Midatech Pharma Us, Inc. 2010-04-16 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Miconazole Nitrate Suppository 200 mg/1 Vaginal Actavis Pharma Company 2002-09-03 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End 3M Cavilon Antifungal Cream 2 g/1000g Topical 3 M Pharmaceuticals 2010-11-30 Not applicable US 7 Day Vaginal Cream 2 g/100g Topical Cardinal Health 2009-03-16 Not applicable US Aloe Vesta Antifungal Ointment 20 mg/g Topical Convatec Inc. 1997-10-03 Not applicable US Aloe Vesta Clear Antifungal Ointment 2 g/100g Topical Convatec Inc. 2013-12-20 Not applicable US Aloe Vesta Clear Antifungal 141g Ointment 2.82 g/141g Topical Guest Packaging Llc. 2016-06-09 Not applicable US Aloe Vesta Clear Antifungal 56g Ointment 1.12 g/56g Topical Guest Packaging Llc. 2016-06-09 Not applicable US Anti-Fungal Cream .02 g/g Topical Universal Distribution Center LLC 2015-04-15 Not applicable US Antifungal Cream 20 mg/g Topical Actavis Pharma Company 2007-05-01 Not applicable US Antifungal Cream 20 mg/g Topical Proficient Rx LP 2007-05-01 Not applicable US Antifungal Cream 2 mg/100mL Topical Mc Kesson 2017-05-26 Not applicable US - International/Other Brands
- Daktarin / Decocort / Femizol-M / Gyno-Daktarin / Miconazex / Monistat / Monistat-Derm / Zeasorb-AF / Zimycan
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End DermaSana Miconazole nitrate (200 mg/mg) + Triclosan (30 mg/mg) Cream Topical Omg Medical Group, Llc 2013-02-14 Not applicable US Monicure Combo Miconazole nitrate (2 %) + Fluconazole (150 mg) Capsule; Cream; Kit Oral; Topical Insight Pharmaceuticals 2012-10-25 Not applicable Canada 
Monistat 1 Combination Pack Miconazole nitrate (1200 mg) + Miconazole nitrate (2 %) Cream; Suppository Topical; Vaginal Insight Pharmaceuticals 1999-02-26 Not applicable Canada Monistat 1 Combination Pack Miconazole nitrate (1200 mg) + Miconazole nitrate (2 %) Cream; Suppository Topical; Vaginal Insight Pharmaceuticals 1999-02-26 Not applicable Canada Monistat 3 Dual-pak Miconazole nitrate (2 %) + Miconazole nitrate (400 mg) Cream; Insert Topical; Vaginal Insight Pharmaceuticals 1986-12-31 Not applicable Canada Monistat 3 Dual-pak Miconazole nitrate (2 %) + Miconazole nitrate (400 mg) Cream; Insert Topical; Vaginal Insight Pharmaceuticals 1986-12-31 Not applicable Canada Monistat 7 Dual-pak Miconazole nitrate (100 mg) + Miconazole nitrate (2 %) Cream; Suppository Topical; Vaginal Insight Pharmaceuticals 1994-12-31 Not applicable Canada Monistat 7 Dual-pak Miconazole nitrate (100 mg) + Miconazole nitrate (2 %) Cream; Suppository Topical; Vaginal Insight Pharmaceuticals 1994-12-31 Not applicable Canada Rash Relief Antifungal Miconazole nitrate (2 g/100g) + Dimethicone (10 g/100g) + Zinc oxide (10 g/100g) Liquid Topical Touchless Care Concepts LLC 2006-06-14 Not applicable US Vusion Miconazole nitrate (2.5 mg/g) + Petrolatum (813.5 mg/g) + Zinc oxide (150 mg/g) Ointment Topical Prestium Pharma, Inc. 2007-05-14 Not applicable US - Categories
- 14-alpha Demethylase Inhibitors
- Anti-Infective Agents
- Antifungal Agents
- Antifungal Agents (Vaginal)
- Antifungals for Dermatological Use
- Antifungals for Topical Use
- Azole Antifungals
- Chemically-Induced Disorders
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2A6 Inhibitors
- Cytochrome P-450 CYP2B6 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2E1 Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Dermatologicals
- Enzyme Inhibitors
- Hormone Antagonists
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Imidazole and Triazole Derivatives
- Imidazoles
- P-glycoprotein/ABCB1 Inhibitors
- Steroid Synthesis Inhibitors
- UNII
- 7NNO0D7S5M
- CAS number
- 22916-47-8
- Weight
- Average: 416.129
Monoisotopic: 413.986023908 - Chemical Formula
- C18H14Cl4N2O
- InChI Key
- BYBLEWFAAKGYCD-UHFFFAOYSA-N
- InChI
- InChI=1S/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2
- IUPAC Name
- 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
- SMILES
- ClC1=CC(Cl)=C(COC(CN2C=CN=C2)C2=C(Cl)C=C(Cl)C=C2)C=C1
Pharmacology
- Indication
For topical application in the treatment of tinea pedis (athlete’s foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor.
- Structured Indications
- Pharmacodynamics
Miconazole is an anti-fungal medication related to fluconazole (Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox), and clotrimazole (Lotrimin, Mycelex). It is used either on the skin or in the vagina for fungal infections. Miconazole was approved by the FDA in 1974. Miconazole prevents fungal organisms from producing vital substances required for growth and function. This medication is effective only for infections caused by fungal organisms. It will not work for bacterial or viral infections.
- Mechanism of action
Miconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Miconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Oral, mouse: LD50 = 3800 mg/kg; Oral, rat: LD50 = 3 gm/kg. Ingestion of the amounts of the components contained in a tube of cream are unlikely to produce overdosage and toxic effects.
- Affected organisms
- Fungi, yeast and protozoans
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Miconazole. Approved Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Miconazole. Approved Acetaminophen The serum concentration of Acetaminophen can be increased when it is combined with Miconazole. Approved Acetohexamide Miconazole may increase the hypoglycemic activities of Acetohexamide. Withdrawn Acetylsalicylic acid The serum concentration of Acetylsalicylic acid can be increased when it is combined with Miconazole. Approved, Vet Approved Afatinib The serum concentration of Afatinib can be increased when it is combined with Miconazole. Approved Aldosterone The serum concentration of Aldosterone can be increased when it is combined with Miconazole. Experimental Alitretinoin The serum concentration of Alitretinoin can be increased when it is combined with Miconazole. Approved, Investigational Ambrisentan The serum concentration of Ambrisentan can be increased when it is combined with Miconazole. Approved, Investigational Amiodarone The metabolism of Miconazole can be decreased when combined with Amiodarone. Approved, Investigational Amitriptyline The serum concentration of Amitriptyline can be increased when it is combined with Miconazole. Approved Amlodipine The risk or severity of adverse effects can be increased when Miconazole is combined with Amlodipine. Approved Amphotericin B The therapeutic efficacy of Amphotericin B can be decreased when used in combination with Miconazole. Approved, Investigational Amrinone The risk or severity of adverse effects can be increased when Miconazole is combined with Amrinone. Approved Apixaban The serum concentration of Apixaban can be increased when it is combined with Miconazole. Approved Aprepitant The serum concentration of Miconazole can be increased when it is combined with Aprepitant. Approved, Investigational Arsenic trioxide The serum concentration of Arsenic trioxide can be increased when it is combined with Miconazole. Approved, Investigational Artesunate The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Miconazole resulting in a loss in efficacy. Approved Atazanavir The metabolism of Miconazole can be decreased when combined with Atazanavir. Approved, Investigational Atenolol The serum concentration of Atenolol can be increased when it is combined with Miconazole. Approved Atomoxetine The metabolism of Miconazole can be decreased when combined with Atomoxetine. Approved Atorvastatin The risk or severity of adverse effects can be increased when Miconazole is combined with Atorvastatin. Approved Axitinib The serum concentration of Axitinib can be increased when it is combined with Miconazole. Approved, Investigational Azelnidipine The risk or severity of adverse effects can be increased when Miconazole is combined with Azelnidipine. Approved Azimilide The risk or severity of adverse effects can be increased when Miconazole is combined with Azimilide. Investigational Barnidipine The risk or severity of adverse effects can be increased when Miconazole is combined with Barnidipine. Approved Belinostat The serum concentration of Belinostat can be increased when it is combined with Miconazole. Approved, Investigational Bencyclane The risk or severity of adverse effects can be increased when Miconazole is combined with Bencyclane. Experimental Benidipine The risk or severity of adverse effects can be increased when Miconazole is combined with Benidipine. Approved Bepridil The risk or severity of adverse effects can be increased when Miconazole is combined with Bepridil. Approved, Withdrawn Betamethasone The serum concentration of Betamethasone can be increased when it is combined with Miconazole. Approved, Vet Approved Boceprevir The metabolism of Miconazole can be decreased when combined with Boceprevir. Withdrawn Bortezomib The metabolism of Miconazole can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Miconazole can be decreased when it is combined with Bosentan. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Miconazole. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Miconazole. Approved Bromocriptine The serum concentration of Bromocriptine can be increased when it is combined with Miconazole. Approved, Investigational Buspirone The metabolism of Buspirone can be decreased when combined with Miconazole. Approved, Investigational Busulfan The serum concentration of Busulfan can be increased when it is combined with Miconazole. Approved, Investigational Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Miconazole. Approved Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Miconazole. Approved Caffeine The serum concentration of Caffeine can be increased when it is combined with Miconazole. Approved Camptothecin The serum concentration of Camptothecin can be increased when it is combined with Miconazole. Experimental Canagliflozin The serum concentration of Canagliflozin can be increased when it is combined with Miconazole. Approved Carbamazepine The metabolism of Miconazole can be increased when combined with Carbamazepine. Approved, Investigational Carboxyamidotriazole The risk or severity of adverse effects can be increased when Miconazole is combined with Carboxyamidotriazole. Investigational Carbutamide Miconazole may increase the hypoglycemic activities of Carbutamide. Experimental Carfilzomib The serum concentration of Carfilzomib can be increased when it is combined with Miconazole. Approved Caroverine The risk or severity of adverse effects can be increased when Miconazole is combined with Caroverine. Experimental Ceritinib The serum concentration of Miconazole can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Cerivastatin can be increased when it is combined with Miconazole. Withdrawn Chlorpromazine The serum concentration of Chlorpromazine can be increased when it is combined with Miconazole. Approved, Vet Approved Chlorpropamide Miconazole may increase the hypoglycemic activities of Chlorpropamide. Approved Cilnidipine The risk or severity of adverse effects can be increased when Miconazole is combined with Cilnidipine. Approved Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Miconazole. Approved Cimetidine The serum concentration of Cimetidine can be increased when it is combined with Miconazole. Approved Cinnarizine The risk or severity of adverse effects can be increased when Miconazole is combined with Cinnarizine. Approved Ciprofloxacin The serum concentration of Ciprofloxacin can be increased when it is combined with Miconazole. Approved, Investigational Cisapride The serum concentration of Cisapride can be increased when it is combined with Miconazole. Approved, Investigational, Withdrawn Cisplatin The serum concentration of Cisplatin can be increased when it is combined with Miconazole. Approved Citalopram The serum concentration of Citalopram can be increased when it is combined with Miconazole. Approved Clarithromycin The metabolism of Miconazole can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Miconazole can be decreased when combined with Clemastine. Approved Clevidipine The risk or severity of adverse effects can be increased when Miconazole is combined with Clevidipine. Approved Clobazam The serum concentration of Clobazam can be increased when it is combined with Miconazole. Approved, Illicit Clomifene The serum concentration of Clomifene can be increased when it is combined with Miconazole. Approved, Investigational Clonidine The serum concentration of Clonidine can be increased when it is combined with Miconazole. Approved Clopidogrel The serum concentration of Clopidogrel can be increased when it is combined with Miconazole. Approved, Nutraceutical Clorindione The serum concentration of Clorindione can be increased when it is combined with Miconazole. Experimental Clotrimazole The metabolism of Miconazole can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The serum concentration of Clozapine can be increased when it is combined with Miconazole. Approved Cobicistat The metabolism of Miconazole can be decreased when combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Miconazole. Approved Colchicine The serum concentration of Colchicine can be increased when it is combined with Miconazole. Approved Conivaptan The metabolism of Conivaptan can be decreased when combined with Miconazole. Approved, Investigational Conjugated estrogens The serum concentration of Conjugated estrogens can be increased when it is combined with Miconazole. Approved Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Miconazole. Approved Crizotinib The metabolism of Miconazole can be decreased when combined with Crizotinib. Approved Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Miconazole. Approved, Investigational, Vet Approved Dabigatran etexilate The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Miconazole. Approved Dabrafenib The serum concentration of Miconazole can be decreased when it is combined with Dabrafenib. Approved Dactinomycin The serum concentration of Dactinomycin can be increased when it is combined with Miconazole. Approved Dapagliflozin The serum concentration of Dapagliflozin can be increased when it is combined with Miconazole. Approved Darodipine The risk or severity of adverse effects can be increased when Miconazole is combined with Darodipine. Experimental Darunavir The metabolism of Miconazole can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Miconazole can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The serum concentration of Daunorubicin can be increased when it is combined with Miconazole. Approved Debrisoquin The serum concentration of Debrisoquin can be increased when it is combined with Miconazole. Approved Deferasirox The serum concentration of Miconazole can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The metabolism of Miconazole can be decreased when combined with Delavirdine. Approved Dexamethasone The serum concentration of Dexamethasone can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved Diazepam The serum concentration of Diazepam can be increased when it is combined with Miconazole. Approved, Illicit, Vet Approved Dicoumarol The serum concentration of Dicoumarol can be increased when it is combined with Miconazole. Approved Didanosine Didanosine can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Diethylstilbestrol The serum concentration of Diethylstilbestrol can be increased when it is combined with Miconazole. Approved Digitoxin The serum concentration of Digitoxin can be increased when it is combined with Miconazole. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Miconazole. Approved Dihydroergocornine The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Miconazole. Approved Dihydroergocristine The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Miconazole. Experimental Dihydroergocryptine The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Miconazole. Experimental Dihydroergotamine The metabolism of Miconazole can be decreased when combined with Dihydroergotamine. Approved Dihydrotestosterone The serum concentration of Dihydrotestosterone can be increased when it is combined with Miconazole. Illicit Diltiazem The risk or severity of adverse effects can be increased when Miconazole is combined with Diltiazem. Approved Diphenadione The serum concentration of Diphenadione can be increased when it is combined with Miconazole. Experimental Dipyridamole The serum concentration of Dipyridamole can be increased when it is combined with Miconazole. Approved Docetaxel The metabolism of Docetaxel can be decreased when combined with Miconazole. Approved, Investigational Dofetilide The metabolism of Dofetilide can be decreased when combined with Miconazole. Approved Domperidone The serum concentration of Domperidone can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved Dotarizine The risk or severity of adverse effects can be increased when Miconazole is combined with Dotarizine. Investigational Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Miconazole. Approved, Investigational Doxycycline The metabolism of Miconazole can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Miconazole can be decreased when combined with Dronedarone. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Miconazole. Approved Efonidipine The risk or severity of adverse effects can be increased when Miconazole is combined with Efonidipine. Approved Elbasvir The serum concentration of Elbasvir can be increased when it is combined with Miconazole. Approved Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Miconazole. Approved, Investigational Enasidenib The serum concentration of Enasidenib can be increased when it is combined with Miconazole. Approved Enzalutamide The serum concentration of Miconazole can be decreased when it is combined with Enzalutamide. Approved Eperisone The risk or severity of adverse effects can be increased when Miconazole is combined with Eperisone. Approved, Investigational Epinastine The serum concentration of Epinastine can be increased when it is combined with Miconazole. Approved, Investigational Ergonovine The risk or severity of adverse effects can be increased when Ergonovine is combined with Miconazole. Approved Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Miconazole. Approved Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Miconazole. Approved, Investigational Erythromycin The metabolism of Miconazole can be decreased when combined with Erythromycin. Approved, Vet Approved Estradiol The serum concentration of Estradiol can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved Estriol The serum concentration of Estriol can be increased when it is combined with Miconazole. Approved, Vet Approved Estrone The serum concentration of Estrone can be increased when it is combined with Miconazole. Approved Ethinyl Estradiol The serum concentration of Ethinyl Estradiol can be increased when it is combined with Miconazole. Approved Ethyl biscoumacetate The serum concentration of Ethyl biscoumacetate can be increased when it is combined with Miconazole. Withdrawn Etoposide The serum concentration of Etoposide can be increased when it is combined with Miconazole. Approved Etravirine The serum concentration of Etravirine can be increased when it is combined with Miconazole. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Miconazole. Approved Ezetimibe The serum concentration of Ezetimibe can be increased when it is combined with Miconazole. Approved Felodipine The risk or severity of adverse effects can be increased when Miconazole is combined with Felodipine. Approved, Investigational Fendiline The risk or severity of adverse effects can be increased when Miconazole is combined with Fendiline. Withdrawn Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Miconazole. Approved Fexofenadine The serum concentration of Fexofenadine can be increased when it is combined with Miconazole. Approved Fidaxomicin The serum concentration of Fidaxomicin can be increased when it is combined with Miconazole. Approved Fluconazole The metabolism of Miconazole can be decreased when combined with Fluconazole. Approved Fluindione The serum concentration of Fluindione can be increased when it is combined with Miconazole. Investigational Flunarizine The risk or severity of adverse effects can be increased when Miconazole is combined with Flunarizine. Approved Fluticasone furoate The serum concentration of Fluticasone furoate can be increased when it is combined with Miconazole. Approved Fluvastatin The serum concentration of Fluvastatin can be increased when it is combined with Miconazole. Approved Fluvoxamine The metabolism of Miconazole can be decreased when combined with Fluvoxamine. Approved, Investigational Fosamprenavir The metabolism of Miconazole can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Miconazole can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Fosphenytoin can be increased when it is combined with Miconazole. Approved Fusidic Acid The serum concentration of Miconazole can be increased when it is combined with Fusidic Acid. Approved Gabapentin The risk or severity of adverse effects can be increased when Miconazole is combined with Gabapentin. Approved, Investigational Gallopamil The risk or severity of adverse effects can be increased when Miconazole is combined with Gallopamil. Investigational Gefitinib The serum concentration of Gefitinib can be increased when it is combined with Miconazole. Approved, Investigational Gemcitabine The serum concentration of Gemcitabine can be increased when it is combined with Miconazole. Approved Glecaprevir The serum concentration of Glecaprevir can be increased when it is combined with Miconazole. Approved Glibornuride Miconazole may increase the hypoglycemic activities of Glibornuride. Withdrawn Gliclazide Miconazole may increase the hypoglycemic activities of Gliclazide. Approved Glipizide Miconazole may increase the hypoglycemic activities of Glipizide. Approved Gliquidone Miconazole may increase the hypoglycemic activities of Gliquidone. Approved Glisoxepide Miconazole may increase the hypoglycemic activities of Glisoxepide. Approved Glyburide Miconazole may increase the hypoglycemic activities of Glyburide. Approved Grazoprevir The serum concentration of Grazoprevir can be increased when it is combined with Miconazole. Approved Grepafloxacin The serum concentration of Grepafloxacin can be increased when it is combined with Miconazole. Withdrawn Haloperidol The serum concentration of Haloperidol can be increased when it is combined with Miconazole. Approved Hydrocortisone The serum concentration of Hydrocortisone can be increased when it is combined with Miconazole. Approved, Vet Approved Ibuprofen The serum concentration of Ibuprofen can be increased when it is combined with Miconazole. Approved Idelalisib The serum concentration of Miconazole can be increased when it is combined with Idelalisib. Approved Imatinib The metabolism of Miconazole can be decreased when combined with Imatinib. Approved Imipramine The serum concentration of Imipramine can be increased when it is combined with Miconazole. Approved Indacaterol The serum concentration of Indacaterol can be increased when it is combined with Miconazole. Approved Indinavir The metabolism of Miconazole can be decreased when combined with Indinavir. Approved Indomethacin The serum concentration of Indomethacin can be increased when it is combined with Miconazole. Approved, Investigational Inotuzumab ozogamicin The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Miconazole. Approved Irinotecan The serum concentration of Irinotecan can be increased when it is combined with Miconazole. Approved, Investigational Isavuconazonium The metabolism of Miconazole can be decreased when combined with Isavuconazonium. Approved, Investigational Isradipine The risk or severity of adverse effects can be increased when Miconazole is combined with Isradipine. Approved Itraconazole The metabolism of Miconazole can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Miconazole can be increased when it is combined with Ivacaftor. Approved Ivermectin The serum concentration of Ivermectin can be increased when it is combined with Miconazole. Approved, Vet Approved Ketazolam The serum concentration of Ketazolam can be increased when it is combined with Miconazole. Approved Ketoconazole The metabolism of Miconazole can be decreased when combined with Ketoconazole. Approved, Investigational Lacidipine The risk or severity of adverse effects can be increased when Miconazole is combined with Lacidipine. Approved Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Miconazole. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Miconazole is combined with Lamotrigine. Approved, Investigational Lansoprazole The serum concentration of Lansoprazole can be increased when it is combined with Miconazole. Approved, Investigational Ledipasvir The serum concentration of Ledipasvir can be increased when it is combined with Miconazole. Approved Lenalidomide The serum concentration of Lenalidomide can be increased when it is combined with Miconazole. Approved Lenvatinib The serum concentration of Lenvatinib can be increased when it is combined with Miconazole. Approved Lercanidipine The risk or severity of adverse effects can be increased when Miconazole is combined with Lercanidipine. Approved, Investigational Levetiracetam The serum concentration of Levetiracetam can be increased when it is combined with Miconazole. Approved, Investigational Levofloxacin The serum concentration of Levofloxacin can be increased when it is combined with Miconazole. Approved, Investigational Levomilnacipran The serum concentration of Levomilnacipran can be increased when it is combined with Miconazole. Approved Lidoflazine The risk or severity of adverse effects can be increased when Miconazole is combined with Lidoflazine. Experimental Linagliptin The serum concentration of Linagliptin can be increased when it is combined with Miconazole. Approved Lisuride The risk or severity of adverse effects can be increased when Lisuride is combined with Miconazole. Approved Loperamide The serum concentration of Loperamide can be increased when it is combined with Miconazole. Approved Lopinavir The metabolism of Miconazole can be decreased when combined with Lopinavir. Approved Losartan The metabolism of Losartan can be decreased when combined with Miconazole. Approved Lovastatin The metabolism of Miconazole can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Miconazole can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Miconazole can be increased when combined with Lumacaftor. Approved Lysergic Acid Diethylamide The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Miconazole. Illicit, Withdrawn Magnesium Sulfate The risk or severity of adverse effects can be increased when Miconazole is combined with Magnesium Sulfate. Approved, Vet Approved Manidipine The risk or severity of adverse effects can be increased when Miconazole is combined with Manidipine. Approved Mannitol The serum concentration of Mannitol can be increased when it is combined with Miconazole. Approved, Investigational Metahexamide Miconazole may increase the hypoglycemic activities of Metahexamide. Experimental Metergoline The risk or severity of adverse effects can be increased when Metergoline is combined with Miconazole. Experimental Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Miconazole. Approved Methylergometrine The risk or severity of adverse effects can be increased when Methylergometrine is combined with Miconazole. Approved Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Miconazole. Approved, Vet Approved Methysergide The risk or severity of adverse effects can be increased when Methysergide is combined with Miconazole. Approved Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Miconazole. Approved, Investigational Mevastatin The serum concentration of Mevastatin can be increased when it is combined with Miconazole. Experimental Mibefradil The risk or severity of adverse effects can be increased when Miconazole is combined with Mibefradil. Withdrawn Midazolam The serum concentration of Midazolam can be increased when it is combined with Miconazole. Approved, Illicit Mifepristone The serum concentration of Miconazole can be increased when it is combined with Mifepristone. Approved, Investigational Mirabegron The serum concentration of Mirabegron can be increased when it is combined with Miconazole. Approved Mitotane The serum concentration of Miconazole can be decreased when it is combined with Mitotane. Approved Mitoxantrone The serum concentration of Mitoxantrone can be increased when it is combined with Miconazole. Approved, Investigational Morphine The serum concentration of Morphine can be increased when it is combined with Miconazole. Approved, Investigational Mycophenolate mofetil The serum concentration of Mycophenolate mofetil can be increased when it is combined with Miconazole. Approved, Investigational Nadolol The serum concentration of Nadolol can be increased when it is combined with Miconazole. Approved Naftopidil The risk or severity of adverse effects can be increased when Miconazole is combined with Naftopidil. Investigational Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Miconazole. Approved Naloxone The serum concentration of Naloxone can be increased when it is combined with Miconazole. Approved, Vet Approved Nefazodone The metabolism of Miconazole can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Miconazole can be decreased when combined with Nelfinavir. Approved Netupitant The serum concentration of Miconazole can be increased when it is combined with Netupitant. Approved Nevirapine The metabolism of Miconazole can be increased when combined with Nevirapine. Approved Nicardipine The risk or severity of adverse effects can be increased when Miconazole is combined with Nicardipine. Approved Nicergoline The risk or severity of adverse effects can be increased when Nicergoline is combined with Miconazole. Approved Nifedipine The risk or severity of adverse effects can be increased when Miconazole is combined with Nifedipine. Approved Niguldipine The risk or severity of adverse effects can be increased when Miconazole is combined with Niguldipine. Experimental Nilotinib The metabolism of Miconazole can be decreased when combined with Nilotinib. Approved, Investigational Niludipine The risk or severity of adverse effects can be increased when Miconazole is combined with Niludipine. Experimental Nilvadipine The risk or severity of adverse effects can be increased when Miconazole is combined with Nilvadipine. Approved Nimesulide The risk or severity of adverse effects can be increased when Miconazole is combined with Nimesulide. Approved, Withdrawn Nimodipine The risk or severity of adverse effects can be increased when Miconazole is combined with Nimodipine. Approved Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Miconazole. Approved Nisoldipine The risk or severity of adverse effects can be increased when Miconazole is combined with Nisoldipine. Approved Nitrendipine The risk or severity of adverse effects can be increased when Miconazole is combined with Nitrendipine. Approved Nizatidine The serum concentration of Nizatidine can be increased when it is combined with Miconazole. Approved Odanacatib The serum concentration of Odanacatib can be increased when it is combined with Miconazole. Investigational Olanzapine The serum concentration of Olanzapine can be increased when it is combined with Miconazole. Approved, Investigational Olaparib The metabolism of Miconazole can be decreased when combined with Olaparib. Approved Ombitasvir The serum concentration of Ombitasvir can be increased when it is combined with Miconazole. Approved Osimertinib The serum concentration of Miconazole can be increased when it is combined with Osimertinib. Approved Otilonium The risk or severity of adverse effects can be increased when Miconazole is combined with Otilonium. Experimental Paclitaxel The serum concentration of Paclitaxel can be increased when it is combined with Miconazole. Approved, Vet Approved Palbociclib The serum concentration of Miconazole can be increased when it is combined with Palbociclib. Approved Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Miconazole. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Miconazole. Approved Pentobarbital The metabolism of Miconazole can be increased when combined with Pentobarbital. Approved, Vet Approved Pergolide The risk or severity of adverse effects can be increased when Pergolide is combined with Miconazole. Approved, Vet Approved, Withdrawn Perhexiline The risk or severity of adverse effects can be increased when Miconazole is combined with Perhexiline. Approved Phenindione The serum concentration of Phenindione can be increased when it is combined with Miconazole. Approved Phenobarbital The metabolism of Miconazole can be increased when combined with Phenobarbital. Approved Phenprocoumon The serum concentration of Phenprocoumon can be increased when it is combined with Miconazole. Approved Pibrentasvir The serum concentration of Pibrentasvir can be increased when it is combined with Miconazole. Approved Pimozide Miconazole may increase the arrhythmogenic activities of Pimozide. Approved Pinaverium The risk or severity of adverse effects can be increased when Miconazole is combined with Pinaverium. Approved Pitavastatin The serum concentration of Pitavastatin can be increased when it is combined with Miconazole. Approved Pomalidomide The serum concentration of Pomalidomide can be increased when it is combined with Miconazole. Approved Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Miconazole. Approved Posaconazole The metabolism of Miconazole can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Pravastatin The serum concentration of Pravastatin can be increased when it is combined with Miconazole. Approved Prazosin The serum concentration of Prazosin can be increased when it is combined with Miconazole. Approved Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Miconazole. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be increased when it is combined with Miconazole. Approved, Vet Approved Pregabalin The risk or severity of adverse effects can be increased when Miconazole is combined with Pregabalin. Approved, Illicit, Investigational Prenylamine The risk or severity of adverse effects can be increased when Miconazole is combined with Prenylamine. Withdrawn Primidone The metabolism of Miconazole can be increased when combined with Primidone. Approved, Vet Approved Progesterone The therapeutic efficacy of Progesterone can be decreased when used in combination with Miconazole. Approved, Vet Approved Propranolol The serum concentration of Propranolol can be increased when it is combined with Miconazole. Approved, Investigational Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Miconazole. Approved Quetiapine The serum concentration of Quetiapine can be increased when it is combined with Miconazole. Approved Quinidine The metabolism of Quinidine can be decreased when combined with Miconazole. Approved Quinine The serum concentration of Quinine can be increased when it is combined with Miconazole. Approved Ranitidine The serum concentration of Ranitidine can be increased when it is combined with Miconazole. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Miconazole. Approved, Investigational Reserpine The serum concentration of Reserpine can be increased when it is combined with Miconazole. Approved Rifabutin The metabolism of Miconazole can be increased when combined with Rifabutin. Approved Rifampicin The metabolism of Miconazole can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Miconazole can be increased when combined with Rifapentine. Approved Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Miconazole. Approved, Investigational Risedronate The risk or severity of adverse effects can be increased when Miconazole is combined with Risedronate. Approved, Investigational Risperidone The serum concentration of Risperidone can be increased when it is combined with Miconazole. Approved, Investigational Ritonavir The metabolism of Miconazole can be decreased when combined with Ritonavir. Approved, Investigational Rivaroxaban The serum concentration of Rivaroxaban can be increased when it is combined with Miconazole. Approved Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Miconazole. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Miconazole. Approved Salicylic acid The serum concentration of Salicylic acid can be increased when it is combined with Miconazole. Approved, Vet Approved Saquinavir The metabolism of Miconazole can be decreased when combined with Saquinavir. Approved, Investigational Selexipag The serum concentration of Selexipag can be increased when it is combined with Miconazole. Approved Sildenafil The metabolism of Miconazole can be decreased when combined with Sildenafil. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Miconazole. Approved Siltuximab The serum concentration of Miconazole can be decreased when it is combined with Siltuximab. Approved Simeprevir The serum concentration of Miconazole can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Miconazole. Approved Sitagliptin The serum concentration of Sitagliptin can be increased when it is combined with Miconazole. Approved, Investigational Sofosbuvir The serum concentration of Sofosbuvir can be increased when it is combined with Miconazole. Approved Solifenacin The metabolism of Solifenacin can be decreased when combined with Miconazole. Approved Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Miconazole. Approved, Investigational Sparfloxacin The serum concentration of Sparfloxacin can be increased when it is combined with Miconazole. Approved Sphingosine The serum concentration of Sphingosine can be increased when it is combined with Miconazole. Experimental St. John's Wort The serum concentration of Miconazole can be decreased when it is combined with St. John's Wort. Nutraceutical Stiripentol The serum concentration of Miconazole can be increased when it is combined with Stiripentol. Approved Sucralfate Sucralfate can cause a decrease in the absorption of Miconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Sulfisoxazole The metabolism of Miconazole can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Sunitinib The metabolism of Sunitinib can be decreased when combined with Miconazole. Approved, Investigational Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Miconazole. Approved, Investigational Tamoxifen The serum concentration of Tamoxifen can be increased when it is combined with Miconazole. Approved Taurocholic Acid The serum concentration of Taurocholic Acid can be increased when it is combined with Miconazole. Experimental Technetium Tc-99m sestamibi The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Miconazole. Approved Telaprevir The metabolism of Miconazole can be decreased when combined with Telaprevir. Withdrawn Telithromycin The metabolism of Miconazole can be decreased when combined with Telithromycin. Approved Temsirolimus The serum concentration of Temsirolimus can be increased when it is combined with Miconazole. Approved Terguride The risk or severity of adverse effects can be increased when Terguride is combined with Miconazole. Experimental Terodiline The risk or severity of adverse effects can be increased when Miconazole is combined with Terodiline. Experimental Tetrahydropalmatine The risk or severity of adverse effects can be increased when Miconazole is combined with Tetrahydropalmatine. Investigational Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Miconazole. Withdrawn Ticagrelor The serum concentration of Ticagrelor can be increased when it is combined with Miconazole. Approved Ticlopidine The metabolism of Miconazole can be decreased when combined with Ticlopidine. Approved Timolol The serum concentration of Timolol can be increased when it is combined with Miconazole. Approved Tioclomarol The serum concentration of Tioclomarol can be increased when it is combined with Miconazole. Experimental Tocilizumab The serum concentration of Miconazole can be decreased when it is combined with Tocilizumab. Approved Tolazamide Miconazole may increase the hypoglycemic activities of Tolazamide. Approved Tolfenamic Acid The risk or severity of adverse effects can be increased when Miconazole is combined with Tolfenamic Acid. Approved Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Miconazole. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Miconazole. Approved, Investigational Toremifene The serum concentration of Toremifene can be increased when it is combined with Miconazole. Approved, Investigational Tranilast The risk or severity of adverse effects can be increased when Miconazole is combined with Tranilast. Approved, Investigational Trastuzumab emtansine The serum concentration of Trastuzumab emtansine can be increased when it is combined with Miconazole. Approved Ubidecarenone The serum concentration of Ubidecarenone can be increased when it is combined with Miconazole. Experimental Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Miconazole. Approved Umeclidinium The serum concentration of Umeclidinium can be increased when it is combined with Miconazole. Approved Vecuronium The serum concentration of Vecuronium can be increased when it is combined with Miconazole. Approved Velpatasvir The serum concentration of Velpatasvir can be increased when it is combined with Miconazole. Approved Venetoclax The serum concentration of Venetoclax can be increased when it is combined with Miconazole. Approved Venlafaxine The metabolism of Miconazole can be decreased when combined with Venlafaxine. Approved Verapamil The risk or severity of adverse effects can be increased when Miconazole is combined with Verapamil. Approved Vinblastine The serum concentration of Vinblastine can be increased when it is combined with Miconazole. Approved Vincristine The serum concentration of Vincristine can be increased when it is combined with Miconazole. Approved, Investigational Vinpocetine The risk or severity of adverse effects can be increased when Miconazole is combined with Vinpocetine. Investigational Vismodegib The serum concentration of Vismodegib can be increased when it is combined with Miconazole. Approved Voriconazole The metabolism of Miconazole can be decreased when combined with Voriconazole. Approved, Investigational Voxilaprevir The serum concentration of Voxilaprevir can be increased when it is combined with Miconazole. Approved Xylometazoline The risk or severity of adverse effects can be increased when Miconazole is combined with Xylometazoline. Approved Ziconotide The risk or severity of adverse effects can be increased when Miconazole is combined with Ziconotide. Approved Zidovudine The serum concentration of Zidovudine can be increased when it is combined with Miconazole. Approved Ziprasidone The metabolism of Miconazole can be decreased when combined with Ziprasidone. Approved Zolpidem The serum concentration of Zolpidem can be increased when it is combined with Miconazole. Approved - Food Interactions
- Not Available
References
- Synthesis Reference
- US3717655
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB15242
- KEGG Drug
- D00882
- KEGG Compound
- C08070
- PubChem Compound
- 4189
- PubChem Substance
- 46506017
- ChemSpider
- 4044
- BindingDB
- 31772
- ChEBI
- 82892
- ChEMBL
- CHEMBL91
- Therapeutic Targets Database
- DAP000154
- PharmGKB
- PA450494
- IUPHAR
- 2449
- Guide to Pharmacology
- GtP Drug Page
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Miconazole
- ATC Codes
- A01AB09 — Miconazole
- A01AB — Antiinfectives and antiseptics for local oral treatment
- A01A — STOMATOLOGICAL PREPARATIONS
- A01 — STOMATOLOGICAL PREPARATIONS
- A — ALIMENTARY TRACT AND METABOLISM
- D01AC — Imidazole and triazole derivatives
- D01A — ANTIFUNGALS FOR TOPICAL USE
- D01 — ANTIFUNGALS FOR DERMATOLOGICAL USE
- D — DERMATOLOGICALS
- A07AC — Imidazole derivatives
- A07A — INTESTINAL ANTIINFECTIVES
- A07 — ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
- A — ALIMENTARY TRACT AND METABOLISM
- J02AB — Imidazole derivatives
- J02A — ANTIMYCOTICS FOR SYSTEMIC USE
- J02 — ANTIMYCOTICS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- G01AF — Imidazole derivatives
- G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
- G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
- G — GENITO URINARY SYSTEM AND SEX HORMONES
- AHFS Codes
- 84:04.08.08 — Azoles
- FDA label
- Download (650 KB)
- MSDS
- Download (73.7 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Actavis Group
- Advanced Pharmaceutical Services Inc.
- Barr Pharmaceuticals
- CVS Pharmacy
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Draxis Specialty Pharmaceuticals Inc.
- Ivax Pharmaceuticals
- Johnson & Johnson Healthcare
- Kaiser Foundation Hospital
- Medisca Inc.
- Ortho Mcneil Janssen Pharmaceutical Inc.
- Orthopedics Advanced Care
- Par Pharmaceuticals
- Perrigo Co.
- Pharmacia Inc.
- Pharmedix
- Physicians Total Care Inc.
- Prescript Pharmaceuticals
- Schering-Plough Inc.
- Southwood Pharmaceuticals
- Dosage forms
Form Route Strength Cream Topical 2 g/1000g Ointment Topical 2.82 g/141g Ointment Topical 1.12 g/56g Cream Topical 2 mg/100mL Powder Topical 2 g/100mL Spray Topical 2 g/100g Cream Topical .02 g/g Spray Topical 20 mg/g Ointment Topical 20 mg/g Cream Topical .02 g/100g Cream Topical Powder Topical 2 g/100g Cream Topical 20 g/1000g Kit Tincture Topical 20 mg/mL Cream Topical 20 mg/mL Aerosol, spray Topical .2 g/10g Cream Topical 20 mg/g Powder Topical 1.42 g/71g Aerosol, powder Topical 20 mg/g Liquid Topical 2 g/100g Cream Topical 2 % Aerosol Topical 2 % Kit Topical; Vaginal Kit Vaginal Suppository Vaginal 400 mg Cream Vaginal 2 g/100g Cream Vaginal 2 mg/100g Suppository Vaginal 100 mg/1 Aerosol, powder Topical 2.6 g/130g Aerosol, spray Topical 1.3 g/130g Aerosol, spray Topical 1.3 g/131g Aerosol, spray Topical 2.6 g/130g Aerosol, spray Topical 3 g/150g Cream Vaginal 20 mg/g Powder Topical 2.6 g/130g Spray Topical 3 g/150g Suppository Vaginal 100 ug/1 Suppository Vaginal 200 mg/1 Powder Topical 20 mg/g Cream Topical .3 g/14g Cream Vaginal 20 mg Capsule; cream; kit Oral; Topical Suppository Vaginal 1200 mg Cream; insert Topical; Vaginal Cream Vaginal 4 % Insert Vaginal 400 mg Cream; suppository Topical; Vaginal Suppository Vaginal 100 mg Cream Vaginal 2 % Cream Topical 200 mg/mg Cream Topical .02 mL/mL Tablet Buccal 50 mg/1 Liquid Topical Cream Topical 2 g/100g Cream Topical 20 mg/100g Cream Topical .7 g/35g Aerosol, powder Topical 2.56 g/128g Cream Vaginal 40 mg/g Ointment Topical 2 g/100g Kit Liquid Topical .3 mg/15mL Ointment Topical Powder Topical 20.6 mg/g - Prices
Unit description Cost Unit Vusion 0.25-15-81.35% Ointment 50 gm Tube 284.34USD tube Miconazole 3 3 200 mg Suppository Box 51.2USD box Monistat-Derm 2% Cream 28.35 gm Tube 41.99USD tube Monistat-Derm 2% Cream 15 gm Tube 32.0USD tube Monistat 1 combination pack 16.81USD each Monistat 7 combination pack 15.96USD each Miconazole Nitrate 2% Cream 28 gm Tube 12.99USD tube Miconazole powder 4.59USD g Monistat 1 6.5% ointment 3.6USD g Miconazole nitrate powder 3.55USD g Vusion ointment 3.17USD g Monistat-derm 2% cream 1.11USD g Miconazole nitrate 2% cream 0.19USD g CVS Pharmacy miconazole 7 cream 0.18USD g Miconazole 7 cream 0.15USD g Antifungal 2% cream 0.1USD g Micatin 2% aerosol spray 0.05USD g Lotrimin af 2% liquid spray 0.04USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5514698 No 1994-03-21 2014-03-21 US US8147852 No 2008-03-30 2028-03-30 US US6153635 No 2000-11-28 2020-11-28 US US6916485 No 2002-09-11 2022-09-11 US US7651698 No 2002-09-11 2022-09-11 US US8518442 No 2002-09-11 2022-09-11 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 159-163 °C Not Available water solubility 1g/100mL (20 °C) Not Available logP 6.1 Not Available - Predicted Properties
Property Value Source Water Solubility 0.000763 mg/mL ALOGPS logP 5.86 ALOGPS logP 5.96 ChemAxon logS -5.7 ALOGPS pKa (Strongest Basic) 6.77 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 27.05 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 103.07 m3·mol-1 ChemAxon Polarizability 39.54 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9735 Blood Brain Barrier + 0.9823 Caco-2 permeable + 0.6096 P-glycoprotein substrate Non-substrate 0.545 P-glycoprotein inhibitor I Non-inhibitor 0.7958 P-glycoprotein inhibitor II Inhibitor 0.8387 Renal organic cation transporter Inhibitor 0.6806 CYP450 2C9 substrate Non-substrate 0.8407 CYP450 2D6 substrate Non-substrate 0.9116 CYP450 3A4 substrate Non-substrate 0.7017 CYP450 1A2 substrate Inhibitor 0.9472 CYP450 2C9 inhibitor Inhibitor 0.939 CYP450 2D6 inhibitor Inhibitor 0.9413 CYP450 2C19 inhibitor Inhibitor 0.9591 CYP450 3A4 inhibitor Inhibitor 0.8861 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.9961 Ames test Non AMES toxic 0.9133 Carcinogenicity Non-carcinogens 0.853 Biodegradation Not ready biodegradable 0.9933 Rat acute toxicity 2.8478 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.5 hERG inhibition (predictor II) Inhibitor 0.8505
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzylethers
- Direct Parent
- Benzylethers
- Alternative Parents
- Dichlorobenzenes / N-substituted imidazoles / Aryl chlorides / Heteroaromatic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organochlorides / Hydrocarbon derivatives
- Substituents
- Benzylether / 1,3-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / N-substituted imidazole / Imidazole / Azole / Heteroaromatic compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- imidazoles, ether, dichlorobenzene (CHEBI:82892) / a small molecule (CPD-4501)
Targets
- Kind
- Protein
- Organism
- Yeast
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Sterol 14-demethylase activity
- Specific Function
- Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
- Gene Name
- ERG11
- Uniprot ID
- P10613
- Uniprot Name
- Lanosterol 14-alpha demethylase
- Molecular Weight
- 60674.965 Da
References
- White TC, Marr KA, Bowden RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998 Apr;11(2):382-402. [PubMed:9564569]
- Ghannoum MA, Rice LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999 Oct;12(4):501-17. [PubMed:10515900]
- Edlind T, Smith L, Henry K, Katiyar S, Nickels J: Antifungal activity in Saccharomyces cerevisiae is modulated by calcium signalling. Mol Microbiol. 2002 Oct;46(1):257-68. [PubMed:12366848]
- Georgopapadakou NH, Walsh TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother. 1996 Feb;40(2):279-91. [PubMed:8834867]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Tetrahydrobiopterin binding
- Specific Function
- Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF)-induce...
- Gene Name
- NOS3
- Uniprot ID
- P29474
- Uniprot Name
- Nitric oxide synthase, endothelial
- Molecular Weight
- 133287.62 Da
References
- Wolff DJ, Datto GA, Samatovicz RA: The dual mode of inhibition of calmodulin-dependent nitric-oxide synthase by antifungal imidazole agents. J Biol Chem. 1993 May 5;268(13):9430-6. [PubMed:7683652]
- Bogle RG, Whitley GS, Soo SC, Johnstone AP, Vallance P: Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol. 1994 Apr;111(4):1257-61. [PubMed:7518297]
- Sennequier N, Wolan D, Stuehr DJ: Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem. 1999 Jan 8;274(2):930-8. [PubMed:9873034]
- Dudek RR, Conforto A, Pinto V, Wildhirt S, Suzuki H: Inhibition of endothelial nitric oxide synthase by cytochrome P-450 reductase inhibitors. Proc Soc Exp Biol Med. 1995 May;209(1):60-4. [PubMed:7536941]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Tetrahydrobiopterin binding
- Specific Function
- Produces nitric oxide (NO) which is a messenger molecule with diverse functions throughout the body. In macrophages, NO mediates tumoricidal and bactericidal actions. Also has nitrosylase activity ...
- Gene Name
- NOS2
- Uniprot ID
- P35228
- Uniprot Name
- Nitric oxide synthase, inducible
- Molecular Weight
- 131116.3 Da
References
- Wolff DJ, Datto GA, Samatovicz RA: The dual mode of inhibition of calmodulin-dependent nitric-oxide synthase by antifungal imidazole agents. J Biol Chem. 1993 May 5;268(13):9430-6. [PubMed:7683652]
- Bogle RG, Whitley GS, Soo SC, Johnstone AP, Vallance P: Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol. 1994 Apr;111(4):1257-61. [PubMed:7518297]
- Sennequier N, Wolan D, Stuehr DJ: Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem. 1999 Jan 8;274(2):930-8. [PubMed:9873034]
- Dudek RR, Conforto A, Pinto V, Wildhirt S, Suzuki H: Inhibition of endothelial nitric oxide synthase by cytochrome P-450 reductase inhibitors. Proc Soc Exp Biol Med. 1995 May;209(1):60-4. [PubMed:7536941]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activati...
- Gene Name
- KCNMA1
- Uniprot ID
- Q12791
- Uniprot Name
- Calcium-activated potassium channel subunit alpha-1
- Molecular Weight
- 137558.115 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Potassium channel regulator activity
- Specific Function
- Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Incr...
- Gene Name
- KCNMB1
- Uniprot ID
- Q16558
- Uniprot Name
- Calcium-activated potassium channel subunit beta-1
- Molecular Weight
- 21797.27 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Potassium channel regulator activity
- Specific Function
- Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Acts...
- Gene Name
- KCNMB2
- Uniprot ID
- Q9Y691
- Uniprot Name
- Calcium-activated potassium channel subunit beta-2
- Molecular Weight
- 27129.37 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Potassium channel regulator activity
- Specific Function
- Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Alte...
- Gene Name
- KCNMB3
- Uniprot ID
- Q9NPA1
- Uniprot Name
- Calcium-activated potassium channel subunit beta-3
- Molecular Weight
- 31603.26 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Potassium channel regulator activity
- Specific Function
- Regulatory subunit of the calcium activated potassium KCNMA1 (maxiK) channel. Modulates the calcium sensitivity and gating kinetics of KCNMA1, thereby contributing to KCNMA1 channel diversity. Decr...
- Gene Name
- KCNMB4
- Uniprot ID
- Q86W47
- Uniprot Name
- Calcium-activated potassium channel subunit beta-4
- Molecular Weight
- 23948.465 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Protein phosphatase binding
- Specific Function
- Forms a voltage-independent potassium channel that is activated by intracellular calcium (PubMed:26148990). Activation is followed by membrane hyperpolarization which promotes calcium influx. Requi...
- Gene Name
- KCNN4
- Uniprot ID
- O15554
- Uniprot Name
- Intermediate conductance calcium-activated potassium channel protein 4
- Molecular Weight
- 47695.12 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Small conductance calcium-activated potassium channel activity
- Specific Function
- Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to ...
- Gene Name
- KCNN1
- Uniprot ID
- Q92952
- Uniprot Name
- Small conductance calcium-activated potassium channel protein 1
- Molecular Weight
- 59986.87 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Small conductance calcium-activated potassium channel activity
- Specific Function
- Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to ...
- Gene Name
- KCNN2
- Uniprot ID
- Q9H2S1
- Uniprot Name
- Small conductance calcium-activated potassium channel protein 2
- Molecular Weight
- 63759.03 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Small conductance calcium-activated potassium channel activity
- Specific Function
- Forms a voltage-independent potassium channel activated by intracellular calcium. Activation is followed by membrane hyperpolarization. Thought to regulate neuronal excitability by contributing to ...
- Gene Name
- KCNN3
- Uniprot ID
- Q9UGI6
- Uniprot Name
- Small conductance calcium-activated potassium channel protein 3
- Molecular Weight
- 82025.305 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Alvarez J, Montero M, Garcia-Sancho J: High affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors. J Biol Chem. 1992 Jun 15;267(17):11789-93. [PubMed:1376313]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
- Specific Function
- Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
- Gene Name
- KCNH2
- Uniprot ID
- Q12809
- Uniprot Name
- Potassium voltage-gated channel subfamily H member 2
- Molecular Weight
- 126653.52 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y: Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005 Mar;144(6):840-8. [PubMed:15778703]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
- Gene Name
- KCNH6
- Uniprot ID
- Q9H252
- Uniprot Name
- Potassium voltage-gated channel subfamily H member 6
- Molecular Weight
- 109923.705 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y: Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005 Mar;144(6):840-8. [PubMed:15778703]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
- Gene Name
- KCNH7
- Uniprot ID
- Q9NS40
- Uniprot Name
- Potassium voltage-gated channel subfamily H member 7
- Molecular Weight
- 134998.525 Da
References
- Hatton CJ, Peers C: Effects of cytochrome P-450 inhibitors on ionic currents in isolated rat type I carotid body cells. Am J Physiol. 1996 Jul;271(1 Pt 1):C85-92. [PubMed:8760033]
- Kikuchi K, Nagatomo T, Abe H, Kawakami K, Duff HJ, Makielski JC, January CT, Nakashima Y: Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol. 2005 Mar;144(6):840-8. [PubMed:15778703]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Partial agonist
- General Function
- Zinc ion binding
- Specific Function
- Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism an...
- Gene Name
- NR1I2
- Uniprot ID
- O75469
- Uniprot Name
- Nuclear receptor subfamily 1 group I member 2
- Molecular Weight
- 49761.245 Da
References
- Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P: Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008 Feb;36(2):339-48. Epub 2007 Nov 12. [PubMed:17998298]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64. [PubMed:15969931]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid 11-beta-monooxygenase activity
- Specific Function
- Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
- Gene Name
- CYP11B1
- Uniprot ID
- P15538
- Uniprot Name
- Cytochrome P450 11B1, mitochondrial
- Molecular Weight
- 57572.44 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxygen binding
- Specific Function
- Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
- Gene Name
- CYP19A1
- Uniprot ID
- P11511
- Uniprot Name
- Aromatase
- Molecular Weight
- 57882.48 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
- Gene Name
- CYP2A6
- Uniprot ID
- P11509
- Uniprot Name
- Cytochrome P450 2A6
- Molecular Weight
- 56501.005 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73. [PubMed:11961113]
- Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
- Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. [PubMed:12235267]
Drug created on June 13, 2005 07:24 / Updated on October 23, 2017 14:13